IOVA
Iovance BiotherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
Current thesis
The stock is depressed versus a median analyst target near $9.56 while Iovance now has a commercial product, a visible launch-conversion setup, and multiple registrational shots on goal beyond current melanoma use.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +4.1.
What can break
Amtagvi demand may not convert cleanly from center onboarding and Proleukin ordering into sustained infusion volume.
Momentum
84
Value
41
Sentiment
61
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.40 · Bull $6.00 · Bear $2.20
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $9.56
Why
Momentum84 · Δ7d +4.1
Value41 · Δ7d +0.0
Sentiment61 · Δ7d +0.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
84
34% active weight
Current posture
7d trendImproving
Δ7d
+4.1
Δ21d
+32.2
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
61
33% active weight
Current posture
7d trendFlat
Δ7d
+0.6
Δ21d
-8.8
Why this grade
Composite grade A. Momentum 83.7 / Value 41.1 / Sentiment 61.2
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.83B
Beta
0.77
Shares Out
385.46M
P/E (TTM) · Derived
-4.3
P/S (TTM)
3.88
P/FCF (TTM) · Derived
-4.48
Rev YoY
+15.2%
EPS YoY
+9.0%
Gross Margin
+24.0%
Op Margin
-166.3%
Net Debt
-$322.78M
Current Ratio
3.41
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology